NCT07163273招募中2 期
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 41
- 试验地点
- 7
- 主要终点
- Determine 6-month Progression Free Survival (PFS)
研究概览
简要总结
A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>18 years of age
- •Histologically proven pancreatic ductal adenocarcinoma, poorly differentiated carcinoma, or adenosquamous carcinoma
- •Radiographic evidence of metastatic disease
- •At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- •Metastatic relapse of previously resected pancreatic cancer is allowed provided the patient is more than 6 months from last SOC adjuvant treatment
- •ECOG PS 0-1
- •Laboratory assessments within 14 days as indicated below:
- •Hemoglobin > 9.0 g/dL (patients with hemoglobin < 9 g/dL may be transfused prior to study enrollment)
- •Platelet count > 100 x 10^9/L
- •Absolute neutrophil count (ANC) > 1.5 x 10^9/L
- •Total bilirubin < 3 x upper limit of normal (ULN)
- •Aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x ULN (if liver metastases are present, AST and ALT < 5 x ULN is permitted.
- •Creatinine ≤1.5 ULN
- •Creatinine clearance > 40 mL/min as calculated by Cockcroft-Gault formula
- •APTT (aPTT) ≤ 1.5 × ULN. For subjects receiving unfractionated heparin < 2.5 × ULN, or within acceptable range considered by the investigator.
- •PT/INR INR ≤ 1.5 × ULN. For subjects receiving warfarin, 2.0 -3.0, or within acceptable range considered by the investigator.
- •Women of childbearing potential must be surgically sterile or postmenopausal or must have a negative pregnancy test (serum or urine) prior to study enrolment and must use effective barrier contraception or abstinence during the treatment period. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions and therefore are not considered effective for this study. Male patients must be surgically sterile or use effective contraception or abstinence during the treatment period. The definition of effective contraception will be based on investigator discretion. Female and male patients are advised to use effective contraceptives for at least 9 months after the last treatment dose.
- •Ability to understand and willing to sign informed consent form
排除标准
- •A history of other disease, metabolic dysfunction, physical examination finding or clinical laboratory test result suspicious of a disease or condition which, in the opinion of the investigator, would compromise patient safety due to risk of treatment complications or could affect interpretation of the study results
- •Ampullary, acinar, squamous, and neuroendocrine histology
- •Presence of central nervous system metastases
- •Life expectancy < 12 weeks
- •Pregnant or breastfeeding women
- •Prior neuropathy > grade 1 as per CTCAE v5
- •Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- •Major surgery within 4 weeks prior to initiation of the study treatment, without full recovery
- •Any past chemotherapy delivered for metastatic pancreatic cancer
- •Known somatic or germline mutations in BRCA1, BRCA2, or PALB2
- •Active second malignancy whose prognosis has a high likelihood of impacting survival
- •Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results. Patients also unwilling or unable to comply with study procedures and/or study visits, including long-term follow-up for survival.
研究组 & 干预措施
NALIRIFOX
Active Comparator
NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15
干预措施: NALIRIFOX (Drug)
Gemcitabine plus nab-Paclitaxel (GnP)
Active Comparator
GnP consists of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, given on Days 1, 8, and 15.
干预措施: Gemcitabine plus nab-Paclitaxel (GnP) (Drug)
结局指标
主要结局
Determine 6-month Progression Free Survival (PFS)
时间窗: 6 months
The primary endpoint is 6-month PFS rate defined as the proportion of patients alive and progression free (by RECIST v.1.1) at 6 months after treatment initiation. PFS events will be classified as either local progression, distant recurrence, secondary malignancy, or death.
次要结局
- Overall Response Rate(24 months)
- Disease Control Rate(24 months)
- Determine Toxicities using the NCI CTCAE v. 5.0(24 months)
- Overall Survival(24 months)
- Time to Treatment Failure(24 months)
研究者
研究点 (7)
Loading locations...
相似试验
招募中
2 期
Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsNCT06835387Tiago Biachi de Castria36
已完成
2 期
Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerMetastatic Colorectal CancerNCT02271464Azienda Ospedaliero, Universitaria Pisana232
招募中
2 期
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialNCT06821997Roswell Park Cancer Institute20
招募中
2 期
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic CancerPancreatic CancerNCT06389760The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School57
招募中
2 期
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaNCT07076212Medical University of South Carolina52